Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors

Xin Yang1 School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing, 100069, People’s Republic of China;3 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Beijing, 100069, People’s Republic of China

https://orcid.org/0000-0003-1125-4404 View further author information

Yifan Wang1 School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing, 100069, People’s Republic of China;3 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Beijing, 100069, People’s Republic of ChinaView further author information

Si Chen1 School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing, 100069, People’s Republic of China;3 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Beijing, 100069, People’s Republic of ChinaView further author information

Shuang Zhang1 School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing, 100069, People’s Republic of China;3 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Beijing, 100069, People’s Republic of ChinaView further author information

Chunying Cui1 School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing, 100069, People’s Republic of China;3 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Beijing, 100069, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information

Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors

Articles from other publishers (10)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors

Citations (10)

Articles from other publishers (10)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date